Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MELK | Q14680 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240151 | 0.80 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL3245454 | 0.79 | CHRNB2 (0.43) | PDK1 | |
| SCHEMBL3240454 | 0.78 | MELK (0.35) | MELKDYRK1A | |
| SCHEMBL3243776 | 0.78 | RPS6KA3 (0.36) | MELKDYRK1A | |
| SCHEMBL3240372 | 0.77 | MET (0.39) | METDOT1LMELKDYRK1APDK1 | |
| SCHEMBL3243674 | 0.75 | MAP2K7 (0.40) | — | |
| SCHEMBL18583568 | 0.71 | ALDH1A1 (0.51) | METDOT1LKCNH2PDK1USP30 | |
| SCHEMBL17888442 | 0.70 | ALDH1A1 (0.53) | METDOT1LKCNH2USP30CHKA | |
| SCHEMBL3245775 | 0.67 | SMN1; SMN2 (0.40) | KCNH2PDK1 | |
| SCHEMBL17886955 | 0.66 | ALDH1A1 (0.49) | METDOT1LKCNH2USP30CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | claimed |
| WO-2009131947-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | CFTR, PKD1, PKD2 | MET 854/4885DOT1L 4676/4885KCNH2 122/4885 |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | MET 575/4885DOT1L 4771/4885KCNH2 362/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | MET 575/4885DOT1L 4771/4885KCNH2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.